Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Diagnostics › Drug Discovery & Development › Relay Therapeutics Initiates Human Study of Selective FGFR2 Inhibitor RLY-4008

Relay Therapeutics Initiates Human Study of Selective FGFR2 Inhibitor RLY-4008

Sep 04, 2020
|
staff reporter

NEW YORK – Clinical stage drug company Relay Therapeutics said on Thursday that it has dosed the first patient in the first-in-human study of RLY-4008 in FGFR2-altered intrahepatic cholangiocarcinoma and other advanced solid tumors.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Apr
08
Featured Webinar

Interpretation of Comprehensive Genomic Profiling from ctDNA Through Clinical Decision Support

Sponsored by
Roche

This webinar will discuss a single-center prospective interventional study that evaluated the success of a targeted therapy selected by profiling of ctDNA and tissue in patients with advanced and refractory carcinoma.

What's Popular?

In Drug Discovery & Development

  1. Kronos Bio to Proceed With Phase III Trial of Entospletinib in NPM1-Mutated AML

  2. After Setbacks, Innate Pharma on Track to Advance NK Cell-based Immunotherapy Pipeline

    Premium

  3. Epizyme Exploring Tazverik Combinations in Basket Trials

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.